Compare Garrett Motion Inc. Common Stock (GTX) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garrett Motion Inc. Common Stock vs Natera Inc. Common Stock — how do they compare? Garrett Motion Inc. Common Stock trades at $25.32 (market cap $4.73B), while Natera Inc. Common Stock trades at $392.78 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 12.1× Garrett Motion Inc. Common Stock's market cap, and Garrett Motion Inc. Common Stock pays a 1.26% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garrett Motion Inc. Common Stock for 6 Days and Natera Inc. Common Stock for 0 Days on average.
| GTX | NTRA | |
|---|---|---|
Market Cap | $4.73B | $57.03B |
Volume | 2,533,396 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $36.23 | $425.64 |
52-Week Low | $12.50 | $179.42 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.99B | $56.18B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garrett Motion (GTX) trades at $25.78, showing minimal daily movement with a 0.08% gain. The stock exhibits bearish technical signals despite strong fundamental performance, including three consecutive quarterly earnings beats and improving profit margins. Recent news highlights the company's leadership in turbocharging and electrification technologies, with Q3 2026 results expected on October 29th. Institutional activity shows significant positions from BlackRock and Deutsche Bank, while analyst consensus remains positive with a $38 price target representing 47% upside potential.
GTX presents a compelling value opportunity with attractive valuation multiples (P/E 14.16, P/S 1.35) and consistent earnings outperformance. However, technical weakness and competitive pressures in automotive technology create near-term headwinds. The upcoming Q3 earnings report on October 29th will be crucial for validating the company's raised 2026 outlook and momentum trajectory.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garrett Motion Inc. Common Stock
Garrett Motion develops turbocharging and air-boosting technologies for vehicles. Its products are used in internal combustion, hybrid, and other vehicle powertrains.
Read more on GTX →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
